75% of lung cancer cases are detected too late. OncoSwab is changing that. Our mission: make early detection accessible with a non-invasive, easy-to-use test. Founded by visionary scientists and supported by the Health Wildcatters Accelerator, Swiss Government's DayOne Tech, and several pre-seed investors, OncoSwab is currently conducting a proof-of-concept trial with the collaboration of top US and European hospitals and lung cancer experts, aiming to save lives worldwide.